Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Black Diamond Therapeutics (BDTX) Profit After Tax (2018 - 2025)

Black Diamond Therapeutics (BDTX) has disclosed Profit After Tax for 3 consecutive years, with -$25.9 million as the latest value for Q4 2021.

  • For the quarter ending Q4 2021, Profit After Tax fell 14.32% year-over-year to -$25.9 million, compared with a TTM value of -$125.6 million through Dec 2021, down 86.75%, and an annual FY2024 reading of -$69.7 million, up 15.48% over the prior year.
  • Profit After Tax was -$25.9 million for Q4 2021 at Black Diamond Therapeutics, up from -$35.1 million in the prior quarter.
  • Across five years, Profit After Tax topped out at -$3.8 million in Q1 2019 and bottomed at -$35.1 million in Q3 2021.
  • Average Profit After Tax over 3 years is -$19.0 million, with a median of -$16.2 million recorded in 2020.
  • The sharpest move saw Profit After Tax crashed 217.27% in 2020, then decreased 14.32% in 2021.
  • Year by year, Profit After Tax stood at -$9.9 million in 2019, then plummeted by 129.12% to -$22.6 million in 2020, then decreased by 14.32% to -$25.9 million in 2021.
  • Business Quant data shows Profit After Tax for BDTX at -$25.9 million in Q4 2021, -$35.1 million in Q3 2021, and -$34.4 million in Q2 2021.